ArticleJACC. Case reports2025
Persistent Angina With Nonobstructive Coronary Artery Disease: Unmasking Coronary Microvascular Dysfunction Post-Oncotherapy.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCoronary microvascular dysfunction (CMD) is frequently the cause of patients presenting with angina with nonobstructed coronary arteries and may have increased prevalence in cancer survivors. CASE SUMMARY: We report a case of refractory angina in a survivor of Hodgkin lymphoma, previously treated with radiotherapy and chemotherapy. After demonstrating unobstructed epicardial arteries, advanced diagnostics including quantitative stress perfusion cardiac magnetic resonance and invasive coronary physiology testing, revealed CMD as a likely sequela of oncotherapy and informed initiation of mechanism-specific treatment. DISCUSSION: CMD may represent an under-recognized cardiotoxicity of oncotherapy. This case highlights the value of formal, multimodal coronary microvascular function assessment to identify CMD and implement stratified management. Future systematic evaluation investigating the relationship and underlying mechanisms of oncotherapy in CMD is warranted. TAKE-HOME MESSAGE: In cancer survivors presenting with angina with nonobstructed coronary arteries, clinicians should have a high index of suspicion for CMD and consider systematic evaluation to guide stratified treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.